Abstract |
Daiichi Sankyo Co Ltd (formerly Daiichi Seiyaku Co Ltd) was developing the oral semisynthetic taxane derivative tesetaxel for the potential treatment of cancer, including colorectal and gastric cancer. However, despite early signs of promise, in November 2006 tesetaxel was removed from Daiichi's development pipeline for failure to show clear benefit over existing, currently marketed agents for cancer chemotherapy.
|
Authors | Maria Roche, Helena Kyriakou, Michael Seiden |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 7
Issue 12
Pg. 1092-9
(Dec 2006)
ISSN: 1472-4472 [Print] England |
PMID | 17209527
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Taxoids
- tesetaxel
|
Topics |
- Animals
- Antineoplastic Agents, Phytogenic
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
- Clinical Trials, Phase I as Topic
- Contraindications
- Drug Evaluation, Preclinical
- Humans
- Neoplasms
(drug therapy)
- Structure-Activity Relationship
- Taxoids
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
|